Zacks Investment Research upgraded shares of SYNERGY PHARMAC (SGYP) from NEUTRAL to OUTPERFORM on July 02, 2014, with a target price of $4.60.
Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on SYNERGY PHARMAC (SGYP),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment